BiotechTube
Hansoh Pharma

Hansoh Pharma

3692.HKPre-clinical
5,000-10,000 employeeshansoh.com

Hansoh Pharmaceutical Group is one of China's premier pharmaceutical companies, specializing in innovative drug development across oncology, central nervous system disorders, and other therapeutic areas. Founded in 1995, the company has successfully commercialized multiple products in China and is expanding its pipeline with novel small molecules and biologics. Hansoh went public on the Hong Kong Stock Exchange in 2019 and continues to invest heavily in R&D to develop first-in-class and best-in-class therapies.

Market Cap
$23.4B
+46.6% period
Pipeline
—
Patents
—
Publications
4
indexed

3692.HK · Stock Price

USD 30.86+9.81 (+46.60%)

Historical price data

AI Company Overview

Hansoh Pharmaceutical Group is one of China's premier pharmaceutical companies, specializing in innovative drug development across oncology, central nervous system disorders, and other therapeutic areas. Founded in 1995, the company has successfully commercialized multiple products in China and is expanding its pipeline with novel small molecules and biologics. Hansoh went public on the Hong Kong Stock Exchange in 2019 and continues to invest heavily in R&D to develop first-in-class and best-in-class therapies.

OncologyCentral Nervous SystemImmunologyBiosimilars

Technology Platform

Integrated drug discovery and development platform focusing on small molecules and biologics with capabilities spanning target identification through commercial manufacturing.

Funding History

1
Total raised:$989M
IPO$989MJun 14, 2019

Opportunities

Significant growth opportunities exist through international expansion, particularly in emerging markets, and successful advancement of late-stage pipeline candidates in high-value oncology and CNS indications.
The company is also well-positioned to benefit from China's healthcare reforms and increasing adoption of innovative therapies.

Risk Factors

Key risks include intense competition from multinational pharmaceutical companies, regulatory uncertainties in China's evolving healthcare landscape, and execution risks associated with multiple ongoing clinical trials.
Patent cliffs for existing products and potential generic competition also pose medium-term challenges.

Competitive Landscape

Hansoh competes with leading Chinese pharmaceutical companies like BeiGene, Innovent Biologics, and Jiangsu Hengrui Medicine, as well as global players including Roche, Novartis, and Pfizer. The company differentiates through its focus on innovative drug development, strong domestic commercial capabilities, and competitive biosimilar portfolio.